Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S, Okubo Y, Komine M, Takahashi K, Torii H, Morita A, Yotsuyanagi H, Watanabe A, Ohtsuki M; Committee for reviewing the safety of molecularly targeted drugs for psoriasis, Japanese Dermatological Association. Saeki H, et al. Among authors: torii h. J Dermatol. 2023 May;50(5):e138-e150. doi: 10.1111/1346-8138.16797. Epub 2023 Apr 1. J Dermatol. 2023. PMID: 37132187
Japanese guidance for use of biologics for psoriasis (the 2013 version).
Ohtsuki M, Terui T, Ozawa A, Morita A, Sano S, Takahashi H, Komine M, Etoh T, Igarashi A, Torii H, Asahina A, Nemoto O, Nakagawa H; Biologics Review Committee of the Japanese Dermatological Association. Ohtsuki M, et al. Among authors: torii h. J Dermatol. 2013 Sep;40(9):683-95. doi: 10.1111/1346-8138.12239. J Dermatol. 2013. PMID: 24033880
Japanese guidance for use of biologics for psoriasis (the 2019 version).
Saeki H, Terui T, Morita A, Sano S, Imafuku S, Asahina A, Komine M, Etoh T, Igarashi A, Torii H, Abe M, Nakagawa H, Watanabe A, Yotsuyanagi H, Ohtsuki M; Biologics Review Committee of the Japanese Dermatological Association for Psoriasis: Chair: Mamitaro Ohtsuki. Saeki H, et al. Among authors: torii h. J Dermatol. 2020 Mar;47(3):201-222. doi: 10.1111/1346-8138.15196. Epub 2020 Jan 8. J Dermatol. 2020. PMID: 31916326
English version of Japanese guidance for use of biologics for psoriasis (the 2022 version).
Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S, Okubo Y, Komine M, Sano S, Torii H, Morita A, Yotsuyanagi H, Watanabe A, Ohtsuki M; Committee for reviewing the safety of molecularly targeted drugs for psoriasis, Japanese Dermatological Association. Saeki H, et al. Among authors: torii h. J Dermatol. 2023 Feb;50(2):e41-e68. doi: 10.1111/1346-8138.16691. Epub 2022 Dec 29. J Dermatol. 2023. PMID: 36582113
Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective post-marketing surveillance.
Torii H, Terui T, Matsukawa M, Takesaki K, Ohtsuki M, Nakagawa H; Japanese Dermatological Association (JDA) PMS committee. Torii H, et al. J Dermatol. 2016 Jul;43(7):767-78. doi: 10.1111/1346-8138.13214. Epub 2015 Dec 24. J Dermatol. 2016. PMID: 26704926
Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.
Abe M, Nishigori C, Torii H, Ihn H, Ito K, Nagaoka M, Isogawa N, Kawaguchi I, Tomochika Y, Kobayashi M, Tallman AM, Papp KA. Abe M, et al. Among authors: torii h. J Dermatol. 2017 Nov;44(11):1228-1237. doi: 10.1111/1346-8138.13956. Epub 2017 Jul 17. J Dermatol. 2017. PMID: 28714180 Free PMC article. Clinical Trial.
432 results